AB0218 NON MEDICAL SWITCH FROM ADALIMUMAB ORIGINATOR TO THE BIOSIMILAR GP2017 IN PATIENTS AFFECTED BY CHRONIC ARTHRITIS

نویسندگان

چکیده

Background: The non-medical switch (NMS) from originator drugs to biosimilars is a possible strategy adopted by rheumatologists in order control the expansion of pharmaceutic costs for treatment fo patients affected chronic arthritis. To date, few real life data on adalimumab (ADA) its are available. Objectives: We aimed evaluate efficacy and safety single-Centre cohort arthritis who switched ADA biosimilar GP2017. Methods: Patients rheumatoid (RA), psoriatic (PA) axial spondyloarthritis (axSpA) already therapy with remission or low disease activity at least 6 months were GP2017 (March- June 2020). Data (DAS28-PCR/CDAI/SDAI; DAPSA; BASDAI), eventual adverse events causes withdrawal collected 2, 4 after switch. Results: 88 enrolled (M/F 36/52; mean age 55.8 ± 12 years; 25 RA, 32 PA, 31 axSpA, duration 6.3 3.8 years). No statistically significant difference was observed median DAS28-PCR/CDAI/SDAI values baseline [1.03 (0.96-3.43) vs. 1.21 (0-3.7) / 0 (0-15) (0-17) 0.5 (0-17.5)], DAPSA [0 (0-12.2) (0-15)] BASDAI (0-4.3) (0-6.4)]. retention rate 93.2%. 6/88 (6.8%) back originator. discontinuation were: reactivation single case (1.1%), subjective reasons/nocebo effect 5/88 cases (5.7%), including: general malaise transient increased blood pressure (n.1), dizziness, paraesthesia, arthralgia, headache itch sine materia (n.1) worsening without objective flare (n.2). Conclusion: This first study showing that NMS represents safe practice maintains current treatment. However, switchback described, mainly attributed nocebo [1]. References: [1]Fleischmann R, Jairath V, Mysler E et al . Nonmedical Switching From Originators Biosimilars: Does Nocebo Effect Explain Treatment Failures Adverse Events Rheumatology Gastroenterology? Rheumatol Ther 7: 35–64 (2020). Disclosure Interests: None declared

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.

Sirs, In pre-approval trials of biosimilars, fewer patients are evaluated as compared with originators. For this reason, some physicians are reluctant to employ biosimilars in clinical practice and prefer originators (1). An original approach to strengthen the clinical evidence supporting biosimilars has recently been described (2-4). According to this method, a network meta-analysis is carried...

متن کامل

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

OBJECTIVE SB5 is a biosimilar agent for adalimumab (ADA). The aim of this study was to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of SB5 in comparison with reference ADA in patients with rheumatoid arthritis (RA). METHODS In this phase III, randomized, double-blind, parallel-group study, patients with moderately to severely active RA despite treatment with methot...

متن کامل

Clinical use of ZRC3197 (Adalimumab Biosimilar) in Patients with Inflammatory Arthritis: A Real-life Experience.

We present our real-life clinical experience of ZRC3197 (Adalimumab Biosimilar) in Indian patients with inflammatory arthritis [spondyloarthropathy (SPA) and rheumatoid arthritis (RA)]. Medical records of these patients were retrospectively retrieved and analysed at our single centre. All the patients had received biosimilar Adalimumab 40 mg every 15 days for initial 3 months. Post 3 months, an...

متن کامل

from linguistics to literature: a linguistic approach to the study of linguistic deviations in the turkish divan of shahriar

chapter i provides an overview of structural linguistics and touches upon the saussurean dichotomies with the final goal of exploring their relevance to the stylistic studies of literature. to provide evidence for the singificance of the study, chapter ii deals with the controversial issue of linguistics and literature, and presents opposing views which, at the same time, have been central to t...

15 صفحه اول

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden

INTRODUCTION A new treatment plan was implemented at Skåne University Hospital, on economic grounds, for children requiring recombinant human growth hormone (rhGH) treatment. This involved switching patients from treatment with originator rhGHs to treatment with a biosimilar rhGH, somatropin (Omnitrope®), using a Dialogue Teamwork approach. The feasibility of using this approach to implement th...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Annals of the Rheumatic Diseases

سال: 2021

ISSN: ['1468-2060', '0003-4967']

DOI: https://doi.org/10.1136/annrheumdis-2021-eular.1563